Payment overview · 2025
General Payments
$432.85
20 reported records · 14 companies
Healthcare provider profile · identity verified
Tariq Khalil, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MESA, AZ · NPI 1750337457
Verified facts
What the public records show
CMS Open Payments records show Tariq Khalil, MD received $432.85 in general payments during 2025 across 20 reported records.
Insulet Corporation accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $53.13 | 12.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.85 | 10.6% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $43.75 | 10.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $43.21 | 10.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.89 | 8.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.84 | 8.1% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $33.35 | 7.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.28 | 7.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.28 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.44 | 5.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.61 | 4.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.48 | 4.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.16 | 3.7% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $5.58 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.85 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $53.13 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.85 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $43.21 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $30.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $5.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 125 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
125 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 157 |
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 156 |
| Lisinopril | Lisinopril | 419 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 373 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 89 |
| Gabapentin | Gabapentin | 245 | 67 |
| Omeprazole | Omeprazole | 238 | 70 |
| Metformin Hcl | Metformin Hcl | 231 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 231 | 63 |
| Simvastatin | Simvastatin | 225 | 63 |
| Losartan Potassium | Losartan Potassium | 221 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 60 |
| Eliquis | Apixaban | 175 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 48 |
| Allopurinol | Allopurinol | 164 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 147 | 39 |
| Ozempic | Semaglutide | 136 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 128 | 55 |
| Jardiance | Empagliflozin | 125 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 125 | 30 |
| Trazodone Hcl | Trazodone Hcl | 122 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 42 |
| Potassium Chloride | Potassium Chloride | 110 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 28 |
| Furosemide | Furosemide | 99 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 21 |
| Trulicity | Dulaglutide | 80 | 12 |
| Sertraline Hcl | Sertraline Hcl | 79 | 22 |
| Alendronate Sodium | Alendronate Sodium | 70 | 16 |
| Tramadol Hcl | Tramadol Hcl | 70 | 34 |
| Amoxicillin | Amoxicillin | 67 | 60 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 20 |
| Carvedilol | Carvedilol | 55 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 14 |
| Montelukast Sodium | Montelukast Sodium | 53 | 13 |
| Mounjaro | Tirzepatide | 53 | 11 |
| Finasteride | Finasteride | 52 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 15 |
| Januvia | Sitagliptin Phosphate | 49 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 11 |
| Azithromycin | Azithromycin | 48 | 43 |
| Prednisone | Prednisone | 46 | 39 |
| Spironolactone | Spironolactone | 46 | 15 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 39 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Atenolol | Atenolol | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 15 |
| Warfarin Sodium | Warfarin Sodium | 39 | 14 |
| Farxiga | Dapagliflozin Propanediol | 36 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 36 | suppressed |
| Acyclovir | Acyclovir | 34 | 15 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 26 | 13 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Clonidine Hcl | Clonidine Hcl | 21 | 13 |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.85 · 20 records | Insulet Corporation | AURYON LASER SYSTEM 100-120 VAC, BREZTRI, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, LEQVIO, OTEZLA, Omnipod, Ozempic, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error